Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

Exclusion Criteria

• •Any other cause of macular oedema
• •Structural damage to the macula precluding a visual potential
• •Optical media opacities not allowing an accurate performance of the protocol examinations
• •Any intraocular surgery within three months prior to inclusion and history of any vitreoretinal surgery
• •Advanced diabetic retinopathy potentially requiring any treatment within six months following inclusion or history of vitreal haemorrhage
• •Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea
• •History of IVT with anti-VEGF or corticosteroids at any time in the study eye
• •Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
• •Significantly worse functional prognosis in the other eye or only eye
• •Women of childbearing potential not willing to use an effective method of contraception during treatment and until at least 3 months after the last treatment
• •Pregnant or lactating women
• •Any systemic auto-inflammatory and auto-immune disease requiring treatment
• •Treatment with high-dose corticosteroids (Prednisone equivalent \>5mg/day), immunosuppressive or immunomodulatory or anti-proliferative agents for any reason
• •Inability or contraindications to undergo the investigated intervention